Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine

Conditions

• Migraine

Eligibility Criteria

Sex

FEMALE

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• Ubrogepant — DRUG
  Oral Tablets
• Placebo for Ubrogepant — DRUG
  Oral Tablets

Study Details

A migraine is a moderate to severe headache typically on one side of the head. A migraine attack is a headache that may be accompanied by throbbing, nausea, vomiting, sensitivity to light and sound, or other symptoms. Menstrual migraine (MM) is defined as migraine attacks that occur within the perimenstrual period (PMP) in at least 2 out of 3 menstrual cycles. The PMP is from 2 days before the onset of menstrual bleeding to 2 days after. This study will assess how safe and effective ubrogepant is in treating menstrual migraine. Adverse Events and change in disease activity will be assessed. Ubrogepant is an investigational drug being developed for short-term prevention of menstrual migraine. Participants will be randomly assigned to one of the 2 groups to receive either ubrogepant or placebo. Around 496 adult female participants with menstrual migraine will be enrolled in approximately 100 sites in the United States and Puerto Rico. Participants will receive oral ubrogepant tablets once daily for 7 consecutive days starting 3 days prior to estimated onset of menses per cycle for 3 PMPs during double-blind period (16 weeks). Eligible participants may continue to receive oral ubrogepant tablets once daily for 7 consecutive days per cycle starting 3 days prior to estimated onset of menses during open-label extension period (52 weeks). There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will collect data daily in electronic diaries and attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

Key Dates

Start date

Sep 10, 2024

Status verified

May 2026

Primary completion

Jun 30, 2027

Completion

Sep 30, 2027

Study Design

Enrollment

496 participants (estimated)

Allocation

RANDOMIZED

Intervention model

SEQUENTIAL

Primary purpose

TREATMENT

Arms

• Experimental: Double-Blind Period: Ubrogepant
  Participants will receive ubrogepant during the double-blind period.
• Experimental: Double-Blind Period: Placebo for Ubrogepant
  Participants will receive placebo during the double-blind period.
• Experimental: Open-Label Extension Period: Ubrogepant
  Eligible participants from Double-Blind period may continue to receive ubrogepant during the open-label extension period.

Primary Outcome Measure

Change From Baseline in Number of Migraine Days Occurring During Perimenstrual Periods (PMPs) Across the Double-Blind Treatment Period [ Time Frame: Up to approximately 16 Weeks ]

Central Contacts

• ABBVIE CALL CENTER
  844-663-3742
  [email protected]

Locations (103)

Find similar trials in Birmingham, AL

Related Studies

• Quality Improvement and Practice Based Research in Neurology Using the EMR
  PHASE4 · Enrolling By Invitation · Endeavor Health · Evanston, Illinois
• Pain Biomarker Study
  PHASE1 · Enrolling By Invitation · The University of Texas Health Science Center, Houston · Houston, Texas
• Objectively Diagnose and Monitor Treatment of Light Sensitivity
  Recruiting · Randy Kardon · Iowa City, Iowa
• Mind Body Balance for Pediatric Migraine
  Recruiting · Children's Hospital Medical Center, Cincinnati · Aurora, Colorado